P53 gene replacement for cancer--interactions with DNA damaging agents.
P53 gene replacement for cancer--interactions with DNA damaging agents.
复制标题
P53 基因替换治疗癌症——与 DNA 损伤剂的相互作用。
DOI：
10.1080/02841860152619160
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Meyn,RE
中科院分区：
文献类型：
--
作者：
Roth,JA;Grammer,SF;Swisher,SG;Komaki,R;Nemunaitis,J;Merritt,J;Meyn,RE
p53基因替代的临床试验提供了信息，将是有用的，在未来的基因治疗策略的设计。直接瘤内注射具有低毒性，因此可以容易地与现有治疗组合。注射后的基因表达可以被记录，并且在存在抗腺病毒免疫应答的情况下发生。重要的是，这种治疗可以导致肿瘤消退或延长稳定期。未来的研究方向将包括开发更有效的载体，使用新的基因，和联合模式的方法。不可切除的肿瘤是肿瘤学中的一个突出问题，已经证实的治疗方法如放疗和化疗控制了不到20%的肺癌。基于所讨论的临床前和临床研究，现在看来，这些常规疗法在与功能性p53基因转移结合使用时可能提供新的潜力。
Clinical trials of p53 gene replacement have provided information that will be useful in the design of future gene therapy strategies. Direct intratumor injection has low toxicity and thus can be readily combined with existing treatments. Post-injection gene expression can be documented and occurs in the presence of an anti-adenovirus immune response. Importantly, this treatment can cause tumor regression or prolonged stabilization. Future research directions will include development of more efficient vectors, use of novel genes, and combined modality approaches. Unresectable tumors are a prominent problem in oncology, with proven therapies such as radiotherapy and chemotherapy controlling less than 20% of lung cancers. Based on the preclinical and clinical studies discussed, it now seems that these conventional therapies may provide renewed potential when used in conjunction with transfer of a functional p53 gene.